Current Headlines

  1. Kazia Therapeutics Expands Oncology Platform With First-In-Class SETDB1 Inhibitor Drug Development Platform 4/13/2026

    Kazia Therapeutics Limited (Nasdaq: KZIA), a clinical-stage oncology company advancing therapies to reprogram cancer biology and overcome treatment resistance, announces the in-licensing of a first-in-class SETDB1-targeted epigenetic drug development platform from QIMR Berghofer.

  2. New AI Tech To Speed Drug Development 4/9/2026

    School of Medicine scientists have developed a bold new approach to drug development and discovery that could dramatically accelerate the creation of new medicines.

  3. C4 Therapeutics Expands Long-Term Partnership With Roche Through New Collaboration Agreement Focused On Discovering And Developing Degrader-Antibody Conjugates (DACs) 4/9/2026

    C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science today announced that it has entered into a new collaboration agreement with Roche (SIX: RO, ROP; OTCQX: RHHBY) to advance research in the emerging degrader-antibody conjugate (DAC) modality.

  4. ANI Pharmaceuticals Announces FDA Approval And Launch Of Isosorbide Mononitrate Tablet 4/8/2026

    ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that following final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA), the Company launched Isosorbide Mononitrate Tablet USP, 10 mg and 20 mg. ANI’s Isosorbide Mononitrate Tablet USP is the generic version of the reference listed drug (RLD) Monoket®.

  5. Plus Therapeutics Granted U.S. FDA Orphan Drug Designation To REYOBIQ™ In Pediatric Malignant Gliomas 4/8/2026

    Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to REYOBIQ™ (rhenium Re186 obisbemeda) for the treatment of pediatric malignant gliomas.

  6. ProQR Announces Partnership With Ginkgo Bioworks And Formation Of AI Advisory Board 4/8/2026

    ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced its AI strategy to enhance discovery on the Axiomer platform, including a partnership with Ginkgo Bioworks and the formation of an AI Advisory Board.

  7. Fifteen Years Alongside Europe's Drug Discovery Teams: Viva Biotech Strengthens Continuity From Discovery To Development And Manufacturing 4/7/2026

    Celebrating over 15 years of collaboration alongside Europe's drug discovery community, Viva Biotech is reaffirming its commitment to the region through operational stability, sustained growth, and scalable collaboration.

  8. Nuvalent Announces Submission Of New Drug Application To FDA For Neladalkib In TKI Pre-Treated Advanced ALK-Positive NSCLC 4/7/2026

    Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced the submission to the U.S. Food and Drug Administration (FDA) of the Company's NDA for neladalkib, an investigational ALK-selective inhibitor, in TKI pre-treated advanced ALK-positive NSCLC.

  9. Alloy Therapeutics Enters Into Multi-Target Collaboration And License Agreement With Biogen For Use Of Alloy's AntiClastic ASO Platform 4/7/2026

    Alloy Therapeutics Inc. (“Alloy”), a biotechnology ecosystem company dedicated to democratizing access to cutting-edge drug discovery technologies, today announced a collaboration and license agreement with Biogen Inc. for the use of Alloy’s novel and proprietary AntiClastic ASO Platform.

  10. Variational AI Releases Enki 4: Major Update To Foundation Model For Small-Molecule Drug Discovery 4/7/2026

    Variational AI today announced the release of Enki 4, a major update to its generative AI platform for small-molecule drug discovery.